US$ 25.68
new glp-1 agonist Guidelines for Type 2 Diabetes in 2025 GLP-1 Receptor Agonists: From Diabetes
Description
GLP-1 Data Survey 2025: GLP-1 Weight Loss, Types of GLP-1 Used, GLP-1 Duration Usage, GLP-1 Side Effects, Satisfaction & more.
Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality

Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence

### Competing Interest Statement ASK, AMM, MCG, JMD, CB, CL, SWB, DJL, PML, DRD, JMC, JPF, YL, ARS, DAT, DWP, SH, RBR, MSL, and DAG are employees and stockholders of Pfizer Inc

Gastric ultrasound identifies increased residual gastric contents in patients on GLP-1 receptor agonists, showing that shorter drug withholding and fasting times are linked to higher aspiration risk before anesthesia.

Purpose of Review This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinsons disease (PD), focusing on body weight regulation and neuroprotection
